Paper326550
Therapeutic effect of prednimustine (LEO 1031) in various types of leukaemia.
Brandt L and 1 other. Eur J Cancer (1965), 1977. Cited by 19 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Therapeutic effect of prednimustine (LEO 1031) in various types of leukaemia. Papers, record 326550. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/326550
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Leukemia | Major topic |
| Prednisolone | Major topic |
| Adolescent | |
| Adult | |
| Aged | |
| Blood Cell Count | |
| Clinical Trials as Topic | |
| Drug Evaluation | |
| Drug Therapy, Combination | |
| Female | |
| Humans | |
| Leukemia, Myeloid, Acute | |
| Male | |
| Middle Aged | |
| Remission, Spontaneous | |
| Vincristine |
Source PubMed
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 7,172,410 | Prednimustine and vincristine compared with cytosine arabinoside and thioguanine for treatment of elderly patients with acute nonlymphoblastic leukemia. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7172410 | PubMed |
| 7,139,848 | A phase II study of prednimustine in acute non-lymphocytic leukemia, smouldering leukemia, and refractory anemia with excess blasts. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7139848 | PubMed |
| 6,951,618 | [Acute leukemias in elderly patients (author's transl)]. | Blut | 1982 | https://conductscience.org/library/papers/6951618 | PubMed |
| 6,640,823 | Disposition of orally administered 14C-prednimustine in cancer patients. | Cancer Chemother Pharmacol | 1983 | https://conductscience.org/library/papers/6640823 | PubMed |
| 6,254,684 | Phase II trial of prednimustine (NSC-134087) in the treatment of small-cell anaplastic carcinoma of the lung. | Cancer Chemother Pharmacol | 1980 | https://conductscience.org/library/papers/6254684 | PubMed |
| 394,873 | Prednimustine in adult acute myeloid leukaemia. | Cancer Chemother Pharmacol | 1979 | https://conductscience.org/library/papers/394873 | PubMed |
| 373,907 | New cancer chemotherapy drugs in Europe. | Cancer Chemother Pharmacol | 1978 | https://conductscience.org/library/papers/373907 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/326550
GET https://conductscience.org/api/papers/v1/326550/authors